000281738 001__ 281738
000281738 005__ 20251013100247.0
000281738 0247_ $$2doi$$a10.1177/13872877251371729
000281738 0247_ $$2pmid$$apmid:40899930
000281738 0247_ $$2ISSN$$a1387-2877
000281738 0247_ $$2ISSN$$a1875-8908
000281738 037__ $$aDZNE-2025-01171
000281738 041__ $$aEnglish
000281738 082__ $$a610
000281738 1001_ $$aŠpeh, Andreja$$b0
000281738 245__ $$aCardiovascular health and cognition in older adults: Variations across recruitment models and European countries in the MOPEAD project.
000281738 260__ $$aAmsterdam$$bIOS Press$$c2025
000281738 3367_ $$2DRIVER$$aarticle
000281738 3367_ $$2DataCite$$aOutput Types/Journal article
000281738 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1760342422_8169
000281738 3367_ $$2BibTeX$$aARTICLE
000281738 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281738 3367_ $$00$$2EndNote$$aJournal Article
000281738 520__ $$aBackgroundThe Models of Patient Engagement for Alzheimer's Disease (MOPEAD) project aimed to identify the most effective and cost-efficient recruitment model for detecting prodromal and mild Alzheimer's disease (AD) across five European countries.ObjectiveTo examine differences in cardiovascular risk factors and cognitive performance among countries and recruitment models using MOPEAD data.MethodsIndividuals aged 65-85 with a high risk for prodromal or mild AD were included. Four recruitment models were used: a web-based screening tool, an open house initiative (OHI), a primary care-based protocol for early detection of cognitive decline, and a tertiary care-based screening at a diabetologist clinic. Participants from Germany, Spain, the Netherlands, Sweden, and Slovenia were recruited. Cardiovascular risk factors were self-reported, and cognition was assessed using The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).ResultsA total of 414 individuals (mean age 71.9, SD = 5.0) were included. Significant differences were observed in physical activity (p < 0.001), with individuals from Sweden and Slovenia being the most active. Dutch participants scored highest on most cognitive measures. Individuals recruited via web-based survey were youngest, most active (61.7%), and had the lowest rates of diabetes (12.0%) and heart disease (6.4%), as well as the best cognitive scores. Those recruited via diabetologist clinics displayed the highest cardiovascular risk and the lowest cognitive performance.ConclusionsThis study unveils significant disparities in cardiovascular health and cognition across recruitment strategies and European countries. The OHI shows promise for future recruitment in the context of disease-modifying AD treatments.
000281738 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281738 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281738 650_7 $$2Other$$aAlzheimer's disease
000281738 650_7 $$2Other$$acardiovascular health
000281738 650_7 $$2Other$$acognition
000281738 650_7 $$2Other$$across-country
000281738 650_7 $$2Other$$aearly diagnosis
000281738 650_7 $$2Other$$aparticipants recruitment
000281738 7001_ $$aBoada, Merce$$b1
000281738 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b2$$udzne
000281738 7001_ $$aVisser, Pieter Jelle$$b3
000281738 7001_ $$aWinblad, Bengt$$b4
000281738 7001_ $$aWimo, Anders$$b5
000281738 7001_ $$aSannemann, Lena$$b6
000281738 7001_ $$aStopar, Nina$$b7
000281738 7001_ $$aZwan, Marisa$$b8
000281738 7001_ $$aRodriguez-Gomez, Octavio$$b9
000281738 7001_ $$aJohansson, Gunilla$$b10
000281738 7001_ $$aAlegret, Montse$$b11
000281738 7001_ $$aRodríguez, Isabel$$b12
000281738 7001_ $$aGurrutxaga, Miren$$b13
000281738 7001_ $$aSotolongo, Oscar$$b14
000281738 7001_ $$aRuiz, Agustin$$b15
000281738 7001_ $$aCantero-Fortiz, Yahveth$$b16
000281738 7001_ $$aKramberger, Milica Gregorič$$b17
000281738 773__ $$0PERI:(DE-600)2070772-1$$a10.1177/13872877251371729$$gp. 13872877251371729$$n4$$p1530 - 1538$$tJournal of Alzheimer's disease$$v107$$x1387-2877$$y2025
000281738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000281738 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281738 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000281738 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000281738 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000281738 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000281738 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000281738 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000281738 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000281738 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-20
000281738 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000281738 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000281738 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000281738 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x0
000281738 980__ $$ajournal
000281738 980__ $$aEDITORS
000281738 980__ $$aVDBINPRINT
000281738 980__ $$aI:(DE-2719)1011102
000281738 980__ $$aUNRESTRICTED